Loading
Breast cancer is the most common malignancy among women worldwide, presenting significant challenges in diagnosis, treatment, and management. In the UAE, breast cancer is not only the most common form of cancer identified in women, but also the leading cause of cancer-related mortality. The complexity and heterogeneity of breast cancer necessitate continuous education for healthcare professionals to stay abreast of the latest developments in the field.
Recent years have seen significant strides in breast cancer research, leading to the development of more precise diagnostic tools and innovative treatment options. Key trends include advancements in imaging and molecular profiling, targeted therapies and immunotherapy, and minimally invasive techniques, leading to better patient outcomes and quality of life. Despite these advancements, there are notable gaps in the translation of research findings into clinical practice. Specific gaps include the lack of knowledge or adoption of new diagnostic tools into clinical practice, the lack of implementation of novel therapies, and the adoption of comprehensive management strategies.
The proposed CPD program aims to address these gaps and bridge the divide between research and practice, ensuring that healthcare professionals are well-informed and capable of delivering the highest standard of care.
Head of Genomics Department, Sultan Qaboos Comprehensive Cancer Center, Oman
Dr. Abeer is a renowned Omani Medical Geneticist with a strong background in genetic disorders and familial cancer syndromes. After graduating with an MD from Sultan Qaboos University, where she was recognized for her academic excellence, Dr. Abeer pursued advanced training in Medical Genetics at the University of Calgary, Canada, and the Royal College of Physicians and Surgeons of London.
Upon returning to Oman, she established the country's first cancer genetics clinic at Sultan Qaboos University Hospital and subsequently led the Genomics department. Currently, Dr. Abeer serves as the Head of Cancer Genomics at the comprehensive cancer care and research center.
A dedicated advocate for patients with rare diseases, Dr. Abeer founded and remains an active member of the Oman Society of Genetic Medicine. Her research interests encompass genomic population screening for multifactorial diseases, genomic premarital screening, and the genomics of Autism Spectrum Disorder.
Stanford University School of Medicine, Director of the Breast Cancer Program at the Stanford Cancer Institute and Associate Director of the Stanford Women's Cancer Center, USA
Dr. Melinda Telli, Professor of Medicine in the Division of Medical Oncology at Stanford University School of Medicine, is Director of the Breast Cancer Program at the Stanford Cancer Institute and Associate Director of the Stanford Women’s Cancer Center. Dr. Telli’s research focuses on the development of novel therapies for the treatment of triple-negative and hereditary cancer. Dr. Telli currently serves as a Komen Scholar, Co-Chair of the American Society of Clinical Oncology Guideline Advisory Group, member of the National Comprehensive Cancer Network Breast Cancer Guideline Panel, member of the Journal of Clinical Oncology Editorial Board and Fellow of the American Society of Clinical Oncology.
Associate Professor of Surgery, Northwell Health, USA
Dr. Mehran Habibi is a renowned breast surgeon, researcher, and innovator, currently serving as Chief of the Breast Program at Staten Island University Hospital and Director of Breast Surgery for the Western Region. Prior to his current roles, Dr. Habibi was the founding director of the Breast Center at Johns Hopkins Bayview Campus, where he led numerous advancements in breast cancer care and research.
With extensive expertise in Oncoplastic and Nipple Sparing mastectomies, risk-reducing mastectomies, and the treatment of rare breast tumors, Dr. Habibi excels in managing complex breast cancer cases. His research focuses on cutting-edge innovations such as wire-free tumor resection, intraoperative margin assessment, and the development of a novel device aimed at enhancing radiation therapy precision.
Dr. Habibi's collaborative work in tissue mechanics, integrating deep learning networks and mechanical markers, has provided new insights into breast cancer diagnosis. His additional research into tumor genomics and the role of the microbiome in breast cancer progression has the potential to revolutionize personalized cancer treatment strategies. A graduate of Islamic Azad University, Dr. Habibi completed his residency at Pennsylvania Hospital and St. Luke’s in Bethlehem, Pennsylvania, followed by a fellowship in Complex Surgical Oncology at the Medical College of Virginia. He also holds an MBA from Virginia Commonwealth University, blending medical and business expertise to optimize patient care.
Dr. Habibi is a leading figure in breast cancer surgery and research, contributing significantly to global health initiatives aimed at advancing personalized cancer care.
Assistant Professor of Surgery, UAE University and Tawam Hospital
Dr. Mouza Saeed Alameri is a breast onco-plastic surgeon at the Tawan Hospital in UAE. Dr. Mouza completed her basic medical training at the UAE University. She then completed her German Board certification for general surgery from the Technical University of Munich and her Fellowship in breast oncoplastic surgery from the University of Cologne. She also has a Masters in Healthcare Leadership from the University of Manchester.
Dr. Mouza is the Initiator and Director of the Cancer Survivorship program, Initiator and Co-founder of First Cancer Genetic Clinic in the UAE, and Director of the Breast Care Centre at Tawam Hospital. She was also an elected member of the Federal National Council of the UAE and is, in fact, the first physician ever to hold this prestigious position in the council.
